NCT03075644 - A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

October 4, 2018

Study Completion Date

October 4, 2018

Conditions

Growth Hormone DisorderAdult Growth Hormone Deficiency

Interventions

DRUG

somapacitan

Once weekly subcutaneous injections (s.c., under the skin)

DRUG

Norditropin

Daily subcutaneous injections (s.c., under the skin)

Trial Locations (12)

Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo

Novo Nordisk Investigational Site, Chiba-shi, Chiba

Novo Nordisk Investigational Site, Fukuoka

Novo Nordisk Investigational Site, Kagoshima

Novo Nordisk Investigational Site, Kobe, Hyogo

Novo Nordisk Investigational Site, Kyoto-shi Kyoto

Novo Nordisk Investigational Site, Okayama, Okayama

Novo Nordisk Investigational Site, Osaka

Novo Nordisk Investigational Site, Sagamihara-shi, Kanagawa

Novo Nordisk Investigational Site, Tokyo

Novo Nordisk Investigational Site, Yamagata-shi, Yamagata

Novo Nordisk Investigational Site, Yokohama, Kanagawa